The recent development of dual-targeting antibodies against EGFR/PI3K/AKT and NOTCH signaling is encouraging, because this dual inhibitor decreased resistance and thus may gain clinical efficacy in triple-negative breast cancer [19]. Here, AKT1 is linked to triple-negative breast carcinoma.